PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1

Guey Shin Wang, Neslihan Martinez, Satyam Sarma, Nitin Mathur, Xander H T Wehrens, Thomas A. Cooper

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Cardiac complications are a common cause of death in individuals with the inherited multisystemic disease myotonic dystrophy type 1 (DM1). A characteristic molecular feature of DM1 is misregulated alternative splicing due to disrupted functioning of the splicing regulators muscleblind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1). CUGBP1 is upregulated in DM1 due to PKC pathway activation and subsequent CUGBP1 protein hyperphosphorylation and stabilization. Here, we blocked PKC activity in a heart-specific DM1 mouse model to determine its pathogenic role in DM1. Animals given PKC inhibitors exhibited substantially increased survival that correlated with reduced phosphorylation and decreased steady-state levels of CUGBP1. Functional studies demonstrated that PKC inhibition ameliorated the cardiac conduction defects and contraction abnormalities found in this mouse model. The inhibitor also reduced misregulation of splicing events regulated by CUGBP1 but not those regulated by MBNL1, suggesting distinct roles for these proteins in DM1 cardiac pathogenesis. The PKC inhibitor did not reduce mortality in transgenic mice with heart-specific CUGBP1 upregulation, indicating that PKC inhibition did not have a general protective effect on PKC-independent CUGBP1 increase. Our results suggest that pharmacological blockade of PKC activity mitigates the DM1 cardiac phenotype and provide strong evidence for a role for the PKC pathway in DM1 pathogenesis.

Original languageEnglish (US)
Pages (from-to)3797-3806
Number of pages10
JournalJournal of Clinical Investigation
Volume119
Issue number12
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Myotonic Dystrophy
Carrier Proteins
Phenotype
Alternative Splicing
Transgenic Mice
Cause of Death
Proteins
Up-Regulation
Phosphorylation
Pharmacology
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. / Wang, Guey Shin; Martinez, Neslihan; Sarma, Satyam; Mathur, Nitin; Wehrens, Xander H T; Cooper, Thomas A.

In: Journal of Clinical Investigation, Vol. 119, No. 12, 01.12.2009, p. 3797-3806.

Research output: Contribution to journalArticle

Wang, Guey Shin ; Martinez, Neslihan ; Sarma, Satyam ; Mathur, Nitin ; Wehrens, Xander H T ; Cooper, Thomas A. / PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. In: Journal of Clinical Investigation. 2009 ; Vol. 119, No. 12. pp. 3797-3806.
@article{ead2382065aa45d0a3e43e53f45d04e3,
title = "PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1",
abstract = "Cardiac complications are a common cause of death in individuals with the inherited multisystemic disease myotonic dystrophy type 1 (DM1). A characteristic molecular feature of DM1 is misregulated alternative splicing due to disrupted functioning of the splicing regulators muscleblind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1). CUGBP1 is upregulated in DM1 due to PKC pathway activation and subsequent CUGBP1 protein hyperphosphorylation and stabilization. Here, we blocked PKC activity in a heart-specific DM1 mouse model to determine its pathogenic role in DM1. Animals given PKC inhibitors exhibited substantially increased survival that correlated with reduced phosphorylation and decreased steady-state levels of CUGBP1. Functional studies demonstrated that PKC inhibition ameliorated the cardiac conduction defects and contraction abnormalities found in this mouse model. The inhibitor also reduced misregulation of splicing events regulated by CUGBP1 but not those regulated by MBNL1, suggesting distinct roles for these proteins in DM1 cardiac pathogenesis. The PKC inhibitor did not reduce mortality in transgenic mice with heart-specific CUGBP1 upregulation, indicating that PKC inhibition did not have a general protective effect on PKC-independent CUGBP1 increase. Our results suggest that pharmacological blockade of PKC activity mitigates the DM1 cardiac phenotype and provide strong evidence for a role for the PKC pathway in DM1 pathogenesis.",
author = "Wang, {Guey Shin} and Neslihan Martinez and Satyam Sarma and Nitin Mathur and Wehrens, {Xander H T} and Cooper, {Thomas A.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1172/JCI37976",
language = "English (US)",
volume = "119",
pages = "3797--3806",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1

AU - Wang, Guey Shin

AU - Martinez, Neslihan

AU - Sarma, Satyam

AU - Mathur, Nitin

AU - Wehrens, Xander H T

AU - Cooper, Thomas A.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Cardiac complications are a common cause of death in individuals with the inherited multisystemic disease myotonic dystrophy type 1 (DM1). A characteristic molecular feature of DM1 is misregulated alternative splicing due to disrupted functioning of the splicing regulators muscleblind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1). CUGBP1 is upregulated in DM1 due to PKC pathway activation and subsequent CUGBP1 protein hyperphosphorylation and stabilization. Here, we blocked PKC activity in a heart-specific DM1 mouse model to determine its pathogenic role in DM1. Animals given PKC inhibitors exhibited substantially increased survival that correlated with reduced phosphorylation and decreased steady-state levels of CUGBP1. Functional studies demonstrated that PKC inhibition ameliorated the cardiac conduction defects and contraction abnormalities found in this mouse model. The inhibitor also reduced misregulation of splicing events regulated by CUGBP1 but not those regulated by MBNL1, suggesting distinct roles for these proteins in DM1 cardiac pathogenesis. The PKC inhibitor did not reduce mortality in transgenic mice with heart-specific CUGBP1 upregulation, indicating that PKC inhibition did not have a general protective effect on PKC-independent CUGBP1 increase. Our results suggest that pharmacological blockade of PKC activity mitigates the DM1 cardiac phenotype and provide strong evidence for a role for the PKC pathway in DM1 pathogenesis.

AB - Cardiac complications are a common cause of death in individuals with the inherited multisystemic disease myotonic dystrophy type 1 (DM1). A characteristic molecular feature of DM1 is misregulated alternative splicing due to disrupted functioning of the splicing regulators muscleblind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1). CUGBP1 is upregulated in DM1 due to PKC pathway activation and subsequent CUGBP1 protein hyperphosphorylation and stabilization. Here, we blocked PKC activity in a heart-specific DM1 mouse model to determine its pathogenic role in DM1. Animals given PKC inhibitors exhibited substantially increased survival that correlated with reduced phosphorylation and decreased steady-state levels of CUGBP1. Functional studies demonstrated that PKC inhibition ameliorated the cardiac conduction defects and contraction abnormalities found in this mouse model. The inhibitor also reduced misregulation of splicing events regulated by CUGBP1 but not those regulated by MBNL1, suggesting distinct roles for these proteins in DM1 cardiac pathogenesis. The PKC inhibitor did not reduce mortality in transgenic mice with heart-specific CUGBP1 upregulation, indicating that PKC inhibition did not have a general protective effect on PKC-independent CUGBP1 increase. Our results suggest that pharmacological blockade of PKC activity mitigates the DM1 cardiac phenotype and provide strong evidence for a role for the PKC pathway in DM1 pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=72849117063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849117063&partnerID=8YFLogxK

U2 - 10.1172/JCI37976

DO - 10.1172/JCI37976

M3 - Article

VL - 119

SP - 3797

EP - 3806

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -